

Supplementary Table S1. Full database-specific search strategies

PubMed

((SGLT2 inhibitor*[Title/Abstract]) OR sodium-glucose cotransporter-2 inhibitor*[Title/Abstract] OR dapagliflozin[Title/Abstract] OR empagliflozin[Title/Abstract] OR canagliflozin[Title/Abstract] OR ertugliflozin[Title/Abstract] OR ipragliflozin[Title/Abstract]) AND ((type 2 diabetes[Title/Abstract]) OR T2DM[Title/Abstract] OR diabetes mellitus, type 2[MeSH Terms]) AND ((hepatocellular carcinoma[Title/Abstract]) OR HCC[Title/Abstract] OR liver cancer[Title/Abstract] OR liver neoplasm*[Title/Abstract]).

Embase

(sglt2 inhibitor*:ti,ab OR sodium glucose cotransporter 2 inhibitor*:ti,ab OR dapagliflozin:ti,ab OR empagliflozin:ti,ab OR canagliflozin:ti,ab OR ertugliflozin:ti,ab) AND (type 2 diabetes:ti,ab OR t2dm:ti,ab) AND (hepatocellular carcinoma:ti,ab OR hcc:ti,ab OR liver cancer:ti,ab).

Cochrane Library

(SGLT2 inhibitor OR sodium-glucose cotransporter-2 inhibitor OR dapagliflozin OR empagliflozin OR canagliflozin OR ertugliflozin OR ipragliflozin) in Title Abstract Keyword AND (type 2diabetes OR T2DM) AND (hepatocellular carcinoma OR HCC OR liver cancer).

Final search date: 15 March 2026.